1. Home
  2. Science
  3. Pipeline

Pipeline

Life sciences are radically improving the chances of treatment, even for diseases that have yet to find therapeutic answers. Thanks to new knowledge of biotechnology, ever-increasing computing power and the advancement of artificial intelligence, we will be able to respond to patients' needs even faster.

Clinical Pipeline

With our research and development pipeline, we target some of the highest-needing therapeutic areas.

Eye

  • Cenegermin - bkbj
    Neurotrophic Keratitis (NK)
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    Marketed
  • Cenegermin - bkbj
    Persistent Corneal Epithelial Defect (PCED)
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    Marketed
  • Cenegermin - bkbj
    Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    Marketed
  • DFL 24498
    Atopic Keratoconjunctivitis (AKC)
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    Marketed
  • Undisclosed molecule
    Ocular Graft vs Host disease (oGvHD)
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    Marketed

Brain

  • Undisclosed molecule
    Neonatal Hypoxic-Ischemic Encephalopathy (NHIE)
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    Marketed
  • Undisclosed molecule
    Cerebral Palsy (CP)
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    Marketed
  • Undisclosed molecule
    Traumatic Brain Injury (TBI)
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    Marketed

Pain

  • DF2755A
    Chronic Pain
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    Marketed
  • DFL 23693
    Osteoarthiritis
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    Marketed

Relevant publications

Human nerve growth factor delivery to the retina: Quantitative methodology and mathematical modeling in preclinical settings

Authors: Simone L Mattioli, Prashant Dogra, Francesco Longobardi, Grazia Casiello, Lucia Apparente, Nicola Detta, Rubina Novelli, Andrea Aramini, Franca Cattani, Maria I Antonangeli, Tiziana Romeo, Marcello Allegretti, Zhihui Wang, Cleide G Machado, Renata Pasqual
PNAS Nexus

Clinical-grade intranasal NGF fuels neurological and metabolic functions of Mecp2-deficient mice

Authors: Diego Pozzer, Marzia Indrigo, Martina Breccia, Elena Florio, Camilla Aurora Franchino, Giuseppina De Rocco, Francesca Maltecca, Antonio Fadda, Marzia Rossato, Andrea Aramini, Marcello Allegretti, Angelisa Frasca, Lidia De Filippis, Nicoletta Landsberger
Brain

Cenegermin for the Treatment of Moderate or Severe Neurotrophic Keratopathy: Results from a Prospective, Phase IV, Open-Label Study in China

Authors: Suxia Li, Jianjiang Xu, Jin Yuan, Zhiqiang Pan, Giacomo Siri, Scott G. Hauswirth, Flavio Mantelli & Weiyun Shi
Ophthalmology & Therapy

The dual non-competitive CXCR1/2 inhibitor ladarixin impairs neutrophil extravasation without altering intravascular adhesion

Authors: Matteo Napoli, Sebastian Sitaru, Agnes Budke, Anna Kammerl, Georgia Querner, Roland Immler, Ina Rohwedder, Sonja Seifert, Bartolo Ferraro, Ludwig Weckbach, Sergio Catz, Andrea Aramini, Pier Giorgio Amendola, Marcello Allegretti, Riccardo Bertini, Monika P
Haematologica

Evaluation of the gastrotolerability of ketoprofen, lysine, and gabapentin co-crystal administration in an in vitro model of gastric epithelium: a proteomic update

Authors: Francesco D'Egidio, Laura Brandolini, Vanessa Castelli, Massimiliano Quintiliani, Andrea Aramini, Annamaria Cimini, Marcello Allegretti, Michele d'Angelo
PLoS One

Unlock the science behind our mission

Browse Dompé’s research portfolio

Google scholar
“

Through our global R&D community and open innovation mindset, we continue to explore the transformative potential of NGF and beyond, turning scientific breakthroughs into therapies that meet patients’ most pressing needs.

”
Marcello Allegretti, Chief Scientific Officer
“

Our pipeline is rooted in rigorous science and inspired by the transformative potential of NGF and other innovative platforms to redefine how we treat diseases of the eye, the brain, and pain.

”
Ahmed Enayetallah, Chief Development Officer

References

  1. Jeonghyun (Esther) Kwon et al., “Emerging Treatments for Persistent Corneal Epithelial Defects,” Vision 9, no. 2 (April 1, 2025): 26, https://doi.org/10.3390/vision9020026.
  2. Jeonghyun (Esther) Kwon et al., “Emerging Treatments for Persistent Corneal Epithelial Defects,” Vision 9, no. 2 (April 1, 2025): 26, https://doi.org/10.3390/vision9020026.
  3. Valérie Biousse and Nancy J Newman, “Diagnosis and Clinical Features of Common Optic Neuropathies,” The Lancet Neurology 15, no. 13 (December 2016): 1355–67, https://doi.org/10.1016/s1474-4422(16)30237-x.
  4. Joseph J. Chen et al., “Atopic Keratoconjunctivitis: A Review,” Journal of the American Academy of Dermatology 70, no. 3 (December 2013): 569–75, https://doi.org/10.1016/j.jaad.2013.10.036.
  5. Brett Bielory and Leonard Bielory, “Atopic Dermatitis and Keratoconjunctivitis,” Immunology and Allergy Clinics of North America 30, no. 3 (August 2010): 323–36, https://doi.org/10.1016/j.iac.2010.06.004.
  6. “Atopic Keratoconjunctivitis,” National Organization for Rare Disorders, May 1, 2025, https://rarediseases.org/mondo-disease/atopic-keratoconjunctivitis/.
  7. Brett Bielory and Leonard Bielory, “Atopic Dermatitis and Keratoconjunctivitis.”
  8. Atopic keratoconjunctivitis - eyewiki, accessed October 7, 2025, https://eyewiki.org/Atopic_Keratoconjunctivitis.
  9. Hasanain Shikari, Joseph H. Antin, and Reza Dana, “Ocular Graft-versus-Host Disease: A Review,” Survey of Ophthalmology 58, no. 3 (May 2013): 233–51, https://www.surveyophthalmol.com/article/S0039-6257(12)00184-1/abstract.
  10. Espana EM, et al. Corneal complications of chronic graft-versus-host disease: prevention and treatment. Cornea. 2010;29(2):119-127.
  11. “Neonatal Hypoxic-Ischemic Encephalopathy,” Nationwide Children’s Hospital, n.d., https://www.nationwidechildrens.org/conditions/health-library/neonatal-hypoxic-ischemic-encephalopathy.
  12. Katie Lavender, ed., “Cerebral Palsy Statistics: Facts and Insights on CP,” Cerebral Palsy Guide, June 17, 2025, https://www.cerebralpalsyguide.com/cerebral-palsy/statistics/#:~:text=Since%20cerebral%20palsy%20affects%20about,is%200.29%25%20of%20the%20population.
  13. Jill Daugherty et al., “Traumatic Brain Injury–Related Deaths by Race/Ethnicity, Sex, Intent, and Mechanism of Injury — United States, 2000–2017,” MMWR. Morbidity and Mortality Weekly Report 68, no. 46 (November 22, 2019): 1050–56, https://doi.org/10.15585/mmwr.mm6846a2.
  14. Rolf-Detlef Treede et al., “Chronic Pain as a Symptom or a Disease: The IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11),” Pain 160, no. 1 (January 2019): 19–27, https://doi.org/10.1097/j.pain.0000000000001384.
  15. Rikard SM, Strahan AE, Schmit KM, Guy GP Jr., “Chronic Pain Among Adults — United States, 2019–2021,” MMWR Morb Mortal Wkly Rep 2023;72:379–385. DOI: http://dx.doi.org/10.15585/mmwr.mm7215a1.
  16. Liping Tong et al., “Current Understanding of Osteoarthritis Pathogenesis and Relevant New Approaches,” Bone Research 10, no. 1 (September 20, 2022), https://doi.org/10.1038/s41413-022-00226-9.
  17. “OA Prevalence and Burden,” Osteoarthritis Action Alliance, https://oaaction.unc.edu/oa-module/oa-prevalence-and-burden/.